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ABSTRACT
Schlemm’s canal (SC) is a unique, complex
vascular structure responsible for maintaining
fluid homeostasis within the anterior segment
of the eye by draining the excess of aqueous
humour. In glaucoma, a heterogeneous group
of eye disorders afflicting approximately 60
million individuals worldwide, the normal
outflow of aqueous humour into SC is progres-
sively hindered, leading to a gradual increase in
outflow resistance, which gradually results in
elevated intraocular pressure (IOP). By and large
available antiglaucoma therapies do not target
the site of the pathology (SC), but rather aim to
decrease IOP by other mechanisms, either
reducing aqueous production or by diverting
aqueous flow through the unconventional out-
flow system. The present review first outlines
our current understanding on the functional
anatomy of SC. It then summarizes existing
research on SC cell properties; first in the con-
text of their role in glaucoma development/
progression and then as a target of novel and
emerging antiglaucoma therapies. Evidence
from ongoing research efforts to develop effec-
tive antiglaucoma therapies targeting SC sug-
gests that this could become a promising site of
future therapeutic interventions.
Keywords: Actin polymerization inhibitors;
Adenosine receptor agonists; Antiglaucoma
drug development; Aqueous humour;
Glaucoma; Intraocular pressure; Nitric oxide
donors; Ophthalmology; Rho Kinase
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INTRODUCTION
Glaucoma is a group of chronic, multifactorial,
and progressive eye disorders that eventually
lead to damage of the optic nerve and irre-
versible visual loss. Given the progressive ageing
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of the world’s population, the number of indi-
viduals affected by glaucoma is projected to
increase to almost 80 million by 2020 [1].
Consequently, there is a pressing need for the
development of novel therapies, which will not
only reduce intraocular pressure (IOP) as cur-
rent therapies generally do but which will also
prevent glaucoma development and slow down
its progression. To succeed this requires inno-
vative biological interventions that will posi-
tively modify the various pathophysiological
processes involved in glaucoma pathogenesis.
In glaucoma, it is established that there is an
impaired balance between deposition and
degradation of extracellular matrix material
(ECM) within the trabecular meshwork (TM).
Gradual accumulation of ECM within the out-
flow system is thought to result in a functional
obstruction leading to a gradual, asymptomatic
elevation of intraocular pressure (IOP) [2]. Ele-
vated IOP is at present the most important
modifiable risk factor for the onset and pro-
gression of glaucoma. The elevation of IOP may
compress TM and result in a collapse of Sch-
lemm’s canal (SC), pathological steps which
also increase outflow resistance and contribute
to the pathobiology of glaucoma development
[3].
At the present time, available glaucoma
therapies aim to obtain a meaningful IOP
reduction to a predetermined target IOP level.
This is achieved by the selection of one or more
classes of topical medications, which are
administered every day in order to meaning-
fully reduce 24-h IOP. Existing antiglaucoma
therapies either reduce IOP by decreasing
aqueous synthesis (b-blockers, carbonic anhy-
drase inhibitors, alpha agonists) or target and
enhance the unconventional uveoscleral out-
flow pathway (prostaglandins). Sadly, contem-
porary glaucoma medications do not target the
conventional outflow system (TM and SC),
which is the site of glaucomatous pathobiology
and the site of anatomical and functional out-
flow obstruction. Drugs that have been shown
to improve conventional outflow have either
been abandoned due to unacceptable side
effects (cholinergics, e.g. pilocarpine), or have a
minimal impact on this outflow site (e.g. bri-
monidine) [4]. It would therefore appear logical
to develop in the future therapies that target the
conventional outflow system. Moreover, it is
not uncommon for available medical therapies
to not sufficiently control IOP. This is due to
their inability to reach an optimal balance
between long-term efficacy, tolerability and
adherence. New medications targeting the
conventional outflow system may provide
adjunctive IOP reduction with superior tolera-
bility allowing a more successful medical
antiglaucoma therapy. This review first sum-
marizes recent advancements in our unde-
standing on SC cell properties and their
contributing role in glaucoma development and
progression. Then, it discusses and explores the
clinical value of targeting SC to better manage
glaucoma in the future.
This article is based on previously conducted
studies, and does not involve any new studies of




Aqueous humour fills the space between the
cornea and the lens, providing nutrients to
these avascular structures that must remain
clear to allow light transmission. It stabilizes
ocular structures, transports neurotransmitters,
provides nutrition, and removes metabolic
by-products, significantly contributing to the
regulation of ocular tissue homeostasis. The
average rate of production of AH is 2.0–2.5
lL min-1, and the turnover rate for aqueous
volume is approximately 1% per minute [5].
Fluctuations in either the synthesis, or more
commonly, the drainage of aqueous can be
responsible for an elevation in IOP. The aque-
ous is constantly produced by three mecha-
nisms: active secretion, diffusion and
ultrafiltration [6]. The most important mecha-
nism is active secretion, mediated by protein
transporters and enzymes, such as Na?–K?-AT-
Pase and carbonic anhydrase, both located in
the non-pigmented and pigmented ciliary
epithelia [7]. This process is responsible for
approximately 80–90% of the total aqueous
formation, and occurs through selective
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trans-cellular movement of anions, cations, and
other molecules across a concentration gradient
in the blood–aqueous barrier. The synthesis by
diffusion comprises the pass of solutes—mainly
hydrophobic—through the lipid portions of the
membrane of the tissues, between the capillar-
ies and the posterior chamber, this process
being proportional to a concentration gradient
across the membrane [8]. The ultrafiltration
mechanism refers to the flow of water and
hydrophilic substances across fenestrated ciliary
capillary endothelia into the ciliary stroma,
depending on an osmotic gradient or hydro-
static pressure [8].
The continuous synthesis of aqueous
humour must be balanced by sufficient aque-
ous drainage through the TM into SC and then
back to the systemic circulation. This system-
atic continuous drainage is named the con-
ventional outflow pathway and comprises
beyond the TM, the juxtacanalicular connec-
tive tissue, the endothelial lining of SC, the
collecting channels, and the aqueous veins.
This pathway provides resistance to aqueous
outflow; in response to this resistance the IOP
gradually rises to a level sufficient to allow the
flow of aqueous across the TM into SC [9].
Thus, aqueous passes through the TM as a bulk
flow driven by the pressure gradient. At stea-
dy-state IOP, aqueous flow rate across the TM
resistance equals the rate of aqueous synthesis
by the ciliary body. Alternative outflow is
provided by the unconventional uveoscleral
pathway where the flow is pressure-indepen-
dent and a proportion of aqueous humour
leaves the eye through the interstitial spaces of
the ciliary body.
SCHLEMM’S CANAL ANATOMY
SC is located at the inner space of the cor-
neoscleral junction, encircling the cornea, and
is responsible for controlling the balance
between secretion and drainage of the aqueous
after it crosses the TM. Filled with blood,
deriving from the ipsilateral episcleral or jugular
vein, SC appears as an irregular red line with a
varying diameter, divided by partitions into
small tributaries, which join together in a
plexiform appearance. In a cross-section, SC
appears as a flattened oval structure between the
sclera spur and Descemet’s membrane, bounded
anterolaterally by the sclera and posteriorly by
the corneoscleral trabeculae. The canal can be
divided into three zones: the endothelial lining,
the basal lamina, and the peri- or
juxta-canalicular connective tissue [10]. The
endothelial lining is formed by a single layer of
delicate spindle-shaped endothelial cells with
wedge-shaped, rounded ends, which are located
parallel to the circumference of the canal. The
endothelial cells show small microvilli on their
apical area, a few projections extended into the
basement membrane in the basal area, and gap
junctions and complex interdigitations between
adjacent and lateral cells [11]. Endothelial cells
contain an elongated nucleus, mitochondria,
rough and smooth endoplasmic reticulum,
golgi apparatus, centrosomes, and pinocytic
vesicles, as well as fine cytoplasmic filaments
and giant vacuolar configurations, which are
believed to play a major role in the bulk outflow
of aqueous across the endothelial barrier [12].
The basement membrane is composed of an
amorphous matrix of an irregular network of
thin microfibril loose sheets, provides anchor-
age to SC endothelial lining. The basement
membrane is separated from the outermost part
of the TM by the pericanalicular connective
tissue [13]. The extracellular spaces of the con-
nective tissue are narrower than those of the TM
and contain hydrophilic glycosaminoglycans
and collagenous material, causing aqueous
outflow resistance and obstructing particulate
material [9]. The basement membrane consists
of loosely arranged mesothelial cells and fixed
endothelial cells, whose ultrastructure appears
similar to that of the endothelial lining and
fibrous tissues, such as collagen fibrils, elastic
fibers, basement membrane material, microfib-
rils, and curly collagen. Fixed endothelial cells
have active phagocytic function and show
shrinking and swelling properties, being able to
alter the porosity of this region and thus par-




As discussed above, the conventional aqueous
pathway consists of the TM, the juxtacanalicu-
lar connective tissue, the endothelial lining of
SC, the collecting channels, and the aqueous
veins, in this order. Among these structures, it is
established that SC offers the greatest resistance
to aqueous outflow, providing a promising
option for the development of IOP-lowering
therapies. The resistance induced at the SC level
is predominantly due to the compact endothe-
lial cell lining, composed by a single layer of
spindle-shaped cells joined with numerous tight
junctions and complex interdigitations between
adjacent and lateral cells [11]. Although even
today the precise mechanism delineating
aqueous drainage is not completely understood,
a key process involved is cytoplasmic vacuole
formation and migration, which drains aqueous
from the TM through the juxtacanalicular tissue
and the endothelial monolayer, into the lumen
of SC [14]. Giant vacuoles are formed in
response to the pressure gradient created by
aqueous flow. Most vacuoles demonstrate a
large opening on the meshwork side of the
vacuole and around one-third also have a distal
opening, forming transcellular and paracellular
pores [15]. Transcellular pores pass from the
basal side of the cell to the apical side at a
location on the cell surface where the inner and
outer surfaces of the cell are joined together and
are fused. The high hydraulic conductivity of SC
appears to be related to the presence of a large
number of these pores, whose diameter ranges
between 0.1 and 2 lm [14]. With regard to the
paracellular pores, they appear to correlate well
with the paracellular flow through SC
endothelium [9]. Small minipores, covered with
a thin diaphragm and with a diameter ranging
from 60 to 65 nm, have also been identified in
the SC inner wall endothelium. Minipores have
similar ultrastructural characteristics to those
forming the fenestrated capillaries in the ciliary
body, or choroid, and thus it has been hypoth-
esized that they are the origin of large tran-
scellular pores [16].
A number of researchers have investigated
the relationship between pore density in SC
endothelium and aqueous humour facility, in
order to determine a possible relationship
between pore number in glaucomatous and
normal eyes [17–19]. However, due to method-
ological differences arising from the fixation
procedure employed, and the fact that pore
density increases with the volume of fixative
perfused through the outflow pathway [20],
results in glaucomatous eyes have been incon-
sistent. This has generated controversy as to the
precise role of inner wall pores in outflow
facility. Despite this, recent studies have
attempted to compare pore density in normal
and glaucomatous eyes. Johnson et al. [19]
established a correlation in the density of
intracellular and border pores between normal
and glaucomatous eyes after correction for the
effects of fixation conditions. They reported
that, even after accounting for the volume of
fixative perfused, glaucomatous eyes exhibit
only 20% of the pore density seen in normal
eyes (160 vs. 835 pores/mm2, respectively).
Consequently, these authors suggested that this
phenomenon may explain the IOP elevation
seen in glaucoma [19]. In 2014, Braakman et al.
[21] perfused fluorescent tracer nanospheres in
non-glaucomatous human donor eyes to
experimentally describe local patterns of out-
flow segmentation through the conventional
route. By confocal and scanning electron
microscopy, they examined the spatial rela-
tionship between inner wall pore density and
tracer intensity. Their results suggested that the
aqueous passed through micron-sized pores in
the inner wall endothelium of SC, and that
paracellular pores played a major role in
transendothelial filtration across the inner wall
in comparison to transcellular pores. The spatial
correlation between pores and tracer suggested
that pores influenced outflow segmentation,
but no insight was offered into the precise nat-
ure of this relationship. These investigators [21]
speculated that the physiological situation rep-
resented a coupled interaction between local
filtration demands and the cellular biome-
chanics involved in giant vacuole and pore
formation.
Adv Ther
In SC cells, vacuole and pore formation is
dependent on pressure and is most likely related
to tissue stiffness. Tissue and cell stiffness are
factors that may significantly modify the
responsiveness of the TM and SC to normal
fluid flow, pressure, and shear stress. Overby
et al. [22] reported that pore formation corre-
lated with the stiffness of the subcortical
cytoskeleton in SC cells as well as that glauco-
matous SC cells exhibited both a stiffer subcor-
tical cytoskeleton and a reduced ability to form
pores. It has been recognized that SC stiffness is
influenced by drug therapies affecting outflow.
Specifically, when a drug stiffened SC cells,
resistance increased, and when a drug therapy
relaxed these cells, outflow resistance decreased.
These observations suggest that those drugs that
will directly or indirectly modify the cytoskele-
ton will decrease cell stiffness and result in
reduced outflow resistance [23–27].
The endothelial lining of SC demonstrates
both blood and lymphatic vascular characteris-
tics, calling into question the longstanding
dogma that the eye lacks lymphatic vessels.
Several years ago, lymphatic markers were
identified in the anterior segment and ciliary
body of the human eye. Nevertheless, it was not
clear whether they were actively involved in the
maintenance of ocular fluid homeostasis
[28, 29]. In a recent study, Hoopes et al. [30]
found that temporal delection of Calcrl, a
highly expressed receptor in lymphatic
endothelial cells, resulted in dilated cor-
neoscleral lymphatic vessels that preceded and
were associated with the formation of corneal
edema and inflammation. Hence, these results
suggested that lymphatic vessels may con-
tribute to the maintenance of fluid homeostasis
and corneal hydration [30]. More recently,
Truong et al. [31] provided the first evidence
showing the expression of the lymphatic mar-
ker Prox-1 on SC endothelium, indicating its
closer similarities with lymphatic endothelium
than with blood endothelium. Likewise,
authors employed a panel of protein markers
that allowed a better identification, isolation,
and characterization of SC endothelial cells,
resulting in improved endothelial cell harvest-
ing efficiency. Therefore, stimulation of SC with
lymphatic-specific therapies may result in a
significant lowering of IOP and could constitute




The precise biomechanics of the resistance to
aqueous humour flow through the conven-
tional outflow pathway is a subject still under
investigation. However, the most popular
hypothesis is that the contractile status of cells
in the aqueous pathway regulate outflow resis-
tance with a key role played by cell stiffness
[32–37]. It is established that drugs such as
bradykinin, dexamethasone, or triamcinolone
are capable of increasing cell stiffness and by
doing so augment outflow resistance, while
other drugs decrease outflow resistance by
relaxing SC cells [12]. In glaucomatous eyes, SC
cells are more sensitive to substrate stiffness
than normal, age-matched SC cells [38], modi-
fying the expression of genes implicated in
outflow obstruction and glaucoma in response
to changes in substrate stiffness, such as the
connective tissue growth factor CTGF [33].
Consequently, targeting the SC level of stiffness
and enhancing outflow facility would appear to
be a promising anti-glaucoma strategy. Further,
this would appear a logical step: decreasing
outflow resistance at the conventional outflow
pathway which is known to be responsible for
regulating the majority of aqueous humour
outflow. The effectiveness of several IOP-low-
ering therapies that focus on the mechanisms
underlying ECM turnover and cell stiffness has
already been successfully demonstrated. These
include adenosine A1 receptor agonists [39–45],
nitric oxide donors [12, 46–48], Rho Kinase
inhibitors [49] and actin depolymerizers
(Tables 1, 2) [23, 25, 26, 50–53].
Adenosine Receptor Agonists
Adenosine is a nucleoside modulator and a
common signaling molecule associated with
cellular responses to stressful situations, such as
eye ischemia that can lead to a rapid elevation
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of adenosine concentration [54]. In the cell,
adenosine is detected in the cytosol; in the
extracellular space adenosine is produced from
ATP, which gets dephosphorylated to AMP and
subsequently to adenosine [55]. The enzymes
involved in the production of adenosine are
ecto-nucleotidases, which are expressed in the
choroid, ciliary body processes and TM [56–58].
Elevated ATP levels in the aqueous humour
have been associated with primary angle-clo-
sure glaucoma and chronic angle-closure glau-
coma [59, 60]. While the mean aqueous
adenosine concentration in healthy eyes is
around 200 nM, in ocular hypertension its
concentration rises to 500 nM, showing a sig-
nificant correlation with elevated IOP [59, 61].
Studies have shown that the effect of adenosine
receptor stimulation on IOP is species-specific.
However, in general, the stimulation of
adenosine A1 receptors lowers IOP in all species
[62]. In rabbits, mice, and monkeys, the use of
adenosine A1 agonists has effectively reduced
IOP [39–43], generating both a decrease in
aqueous flow and an increase in outflow facility
[40, 41, 43]. Further, Shearer and Crosson [44]
provided convincing evidence for the presence
of adenosine A1 receptors on trabecular cells.
These authors concluded that the activation of
these receptors leads to a rapid secretion of
MMP-2, and supported the notion that the
increase in outflow facility involves the activa-
tion of adenosine A1 receptors on TM cells.
In vivo studies in rabbits have shown that
the topical administration of the relatively
selective A1 adenosine receptor agonist
R-phenylsopropyladenosine (R-PIA) produced a
biphasic effect, with a 8.4-mm Hg rise at
30 min and a maximum IOP reduction of
Table 1 Summary of new drugs included in the review that have been employed in preclinical studies to reduce intraocular
pressure in glaucoma by targeting the conventional outﬂow system
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Latrunculin [25, 26, 50, 52, 89]
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5.8 mm Hg 5 h after administration [40]. The
same was observed in normotensive cynomol-
gus monkeys, where a single dose of the ade-
nosine receptor agonists R-PIA (100 lg) and
CHA (N6-cyclohexyladenosine, 500 lg) resulted
in an IOP rise of 4 mm Hg within 30 min,
followed by an IOP reduction of 2–3.5 mm Hg
2–6 h after administration [41]. Studies in rab-
bits and monkeys have explained the biphasic
effect observed in IOP, by a mechanism that
involves the activation of both adenosine A1
and A2 receptors, the latter being responsible
for the initial IOP rise. With regard to adverse
events, the use of adenosine receptor agonists
can produce a mild transient anterior chamber
flare, this effect being observed in monkeys
treated with 250 lg of R–PIA, and indicating a
possible breakdown of the blood-aqueous bar-
rier [41].
Nitric Oxide Donors
Nitric oxide (NO) is a mediator generated
endogenously from L-arginine by a family of
enzymes named NO synthases (NOS), and sig-
naled via the second messenger cGMP [47]. In
healthy eyes, the aqueous humour outflow
pathway and ciliary muscle are sites of NO
synthesis from endothelial NOS. This mecha-
nism, however, is implicated in the abnormal
IOP homeostasis in primary open-angle glau-
coma (POAG) patients as well as in animal
glaucoma models [63]. In POAG eyes, NO syn-
thase activity is decreased in the TM, SC and
ciliary muscle tissues suggesting a relationship
with IOP elevation [64]. In contrast to normal
eyes, lower levels of both NO end-products and
cGMP are detected in the aqueous humour of
POAG patients [65]. Although the site of NO
Table 2 Summary of clinical trials included in the review to evaluate new medications targeting the conventional outﬂow
system, for the treatment of ocular hypertension in glaucoma
Type Drug Clinical trial identiﬁer Number of subjects References






Nitric oxide donors BOL-303259-X NCT01223378 396 [96]
NCT01749904 421 –
Rho Kinase inhibitors AR-13324 NCT01528787 85 [98]
NCT01731002 213 [99]
PG324 NCT02207491 292 [100]
NCT02674854 Recruiting –
K-115 JAPIC090708 28 [103]
JAPIC111700 205 [104]
– 92 [105]
Actin polymerization inhibitors INS115644 NCT00443924 14 [106]
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activity responsible for increasing conventional
outflow facility is currently unknown, a number
of studies have proposed that TM cells and SC
cells might be involved in this process [66–68].
Ashpole et al. [69] established that human
SC cells respond to shear stress in a similar
fashion to that of other vascular endothelia. In
their study, SC cells reacted to physiological
levels of shear stress by aligning with the
direction of flow and by increasing production
of NO. Interestingly, these investigators also
found that SC cells isolated from glaucomatous
eyes were either shear-unresponsive, or lifted
from their substrate in the presence of shear
stress, suggesting that NO production by SC
cells exhibited a homeostatic signaling function
during times of elevated IOP, when SC narrows
and shear stress on SC cells increases [69].
Accordingly, NO-donating drugs may be of
interest as they could provide greater and more
efficient IOP control in glaucoma. To date, it
has been demonstrated that NO-donating
compounds effectively increase conventional
outflow facility and lower IOP in mice, rabbits,
pigs, dogs, monkeys, and humans [46, 67, 70].
Borghi t al. [46] evaluated the use of NCX
125, a NO-donating latanoprost acid synthe-
sized compound, in the rabbit, dog, and pri-
mate experimental glaucoma models. The
hypotensive efficacy obtained with NCX 125
was compared with a commercial formulation
of latanoprost [46]. Notably, NCX 125 exhibited
greater IOP-lowering efficacy in all cases. In
rabbits, the effects were maximal between 30
and 90 min with an IOP difference versus
commercial latanoprost of 10.1 ± 2.3 mm Hg.
The pharmacokinetics of latanoprost-free acid
in the aqueous and iris ciliary body after the
instillation of NCX 125 compared with latano-
prost did not differ significantly between study
groups. In dogs, the maximum effect occurred
4 h after administration of NCX 125, which was
significantly greater in comparison to that
observed after latanoprost treatment
(-6.7 ± 1.2 vs. -10.6 ± 2.3 mm Hg, respec-
tively). In non-human primates, NCX 125
therapy reduced IOP by -16.7 ± 2.2 mm Hg
(Tmax 240 min), while the equivalent dose of
latanoprost resulted in a smaller decline in IOP
(-11.9 ± 3.7 mm Hg, Tmax 360 min).
In a different study with NO-donating lata-
noprost, Krauss et al. [47] investigated the effi-
cacy of BOL-303259-X in preclinical models of
hypertensive glaucoma. The levels of latano-
prost acid were measured in rabbit and primate
aqueous humour, corneas, and iris/ciliary body
following the topical administration of
BOL-303259-X and latanoprost. Levels of lata-
noprost acid in all ocular compartments were
elevated to a similar extent regardless of the
treatment received in both rabbits and mon-
keys, although the limited sample size in mon-
keys (n = 2) did not allow a proper statistical
evaluation of differences in this species. In the
same study, IOP-lowering activity was also
evaluated in an experimental canine glaucoma
model, in which the peak IOP reduction was
-13.2 ± 1.5 mmHg and the effect was evident
for at least 6 h post-instillation. A similar dose
of latanoprost whilst significantly reducing IOP
was not as effective as the NO-donating com-
pound (-7.1 ± 1.8 mmHg), and demonstrated a
slower onset of action. In laser-induced ocular
hypertensive primates, BOL-303259-X was tes-
ted with 3.6-lg (0.012%), 9-lg (0.030%) and
36-lg (0.12%) dosing. While the lowest dose
was inactive when compared to the respective
vehicle, doses of 9 and 36 lg significantly
decreased IOP with a peak reduction relative to
baseline of -15.2 ± 4.9 and -13.5 ± 3.0 mm
Hg, respectively. In contrast, the highest IOP
reduction obtained with latanoprost, with a
30-lg (0.10%) dosing regimen, was still inferior
to that of the novel compound
(-11.9 ± 3.8 mm Hg) [47].
In a more recent study, Impagnatiello et al.
[48] compared the IOP-lowering activity of NCX
470, a novel NO-donating bimatoprost, with
equivalent dosage of bimatoprost in ocular
hypertensive rabbits, ocular normotensive dogs,
and hypertensive non-human primates. This
novel compound was effective in lowering IOP
in all 3 animal models, and a repeated daily
dosing of NCX 470 in dogs resulted in sustained
IOP-lowering activity over time. In general,
NCX 470 was around 3 times more potent than
bimatoprost, as the 0.014% dose of NCX 470
was as effective as the 0.03% dose of bimato-
prost (-4.8 ± 0.5 vs. -3.2 ± 0.9 mm Hg,
respectively). The tested NO-donating
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bimatoprost compound lowered IOP progres-
sively and reached maximum efficacy between
6 and 24 h after administration. In hypertensive
non-human primates, the maximum IOP-low-
ering activity was obtained 24 h post-dosing
(-6.3 ± 1.7 mm Hg) and was superior to that of
bimatoprost (-2.1 ± 1.6 mm Hg).
To date, cumulative evidence with available
experimental glaucoma models supports the
notion that the IOP-lowering activity of
NO-donating prostaglandin analogs exceeds
that of commercially available prostaglandin
analogs. This is thought to be owed to the
concomitant action of the NO and pros-
taglandin moieties. However, although the
therapeutic efficacy of these compounds seems
beyond doubt, further research is needed to
address their potential ocular toxicity and their
clinical efficacy and safety in controlled studies
in humans.
Rho Kinase Inhibitors
Rho Kinases (ROCKs) are serine/theronine
kinases that exist as two isoforms, ROCK1 and
ROCK2, and appear to have several actin
cytoskeletal-related targets, which directly
influence the contractile properties of TM and
SC tissues. ROCKs inhibit myosin light chain
phosphatase, mediating actin cytoskeletal
changes and induce vasoconstriction [71].
Moreover, they stabilize filamentous actin and
reduce cell migration by activating LIM kinases
via phosphorylation [72]. Other targets of
ROCKs comprise the phosphoprotein phos-
phatase inhibitor CPI-17 and the ezrin/radix-
in/moesin family of actin-binding proteins [27].
In humans, ROCK1 and ROCK2 tend to be
expressed in the majority of tissues, including
TM and ciliary muscle cells [73]. The catalytic
activity of ROCKs is activated in response to
Rho binding as well as binding of certain lipids,
such as arachidonic acid, which is able to
induce a five- to sixfold activation of the
enzyme [73, 74]. RhoA is a small guanosine
triphosphate GTP-binding protein that belongs
to the Rho family and regulates aspects of cell
shape, motility, proliferation, and apoptosis
throughout the body [72]. By binding to GTP,
RhoA activates ROCK1 and ROCK2, which sig-
nal downstream molecules to polymerize actin
fibers in the cardiovascular, pulmonary, and
renal systems [75, 76]. In the eye, RhoA has
been detected in the optic nerve of glaucoma-
tous eyes, supporting the relationship between
Rho proteins and glaucoma pathophysiology
[77]. Therefore, ROCKs may play a role in
glaucoma pathogenesis, and Rho Kinase inhi-
bitors may become a new therapeutic tool in
our efforts to reduce IOP by modifying acto-
myosin activity [78].
The effectiveness of RhoA kinase inhibitor
Y-27632 in increasing aqueous humour outflow
facility was evaluated by Honjo et al. [79]. In
cultured human TM cells, Y-27632 successfully
induced retraction and thinning of cells after
30–60 min, as well as a high alteration of F-actin
distribution. Outflow facility, IOP and
uveoscleral outflow were evaluated after topical,
intracameral, and intravitreal administration in
Japanese rabbits. By topical administration,
authors reported a significant IOP decrease after
30 min. Intracameral and intravitreal injections
provided significant IOP lowering between 30
min and 24 h. Eyes treated with Y-27632 expe-
rienced a twofold increase in outflow facility in
comparison with control (0.24 ± 0.02 vs.
0.12 ± 0.01 lL min-1, respectively). With regard
to safety these authors did not observe anterior
chamber, lens, or fundus abnormalities by slit
lamp examination for any of the three admin-
istration routes employed. In another experi-
mental study Rosenthal et al. [80] incubated
small TM strips, dissected from freshly enucle-
ated bovine eyes, with Y-27632 to evaluate its
effect on the contractility of the tissue. The
initial contraction produced by endothelin-1
and carbachol was significantly reduced with a
20-min pre-incubation of the tissue with the
ROCK inhibitor.
In 2009, Fukunaga et al. [81] evaluated the
effect of the ROCK inhibitor HA-1077 in an
animal model of ocular hypertension. For the
evaluation, HA-1077 was dissolved in phos-
phate-buffered saline to be instilled on rabbits
at 1, 2 or 3 mM. These authors reported a
maximal concentration-dependent IOP reduc-
tion that occurred 120 min after the instillation
(-17.4%, -27.3% and -46.4%, for 1, 2, and
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3 mM, respectively). Although no abnormalities
of the anterior chamber or fundus were
observed, minor conjunctival hyperaemia was
noticed in a few cases of eyes treated with 3 mM
HA-1077.
In a similar study, the hypotensive effect of a
different ROCK inhibitor, named H-1152P, was
evaluated in normal and hypertensive rabbit eyes
[82]. H-1152P significantly reduced both normal
and elevated IOP in these animals in a time- and
dose-dependent manner. The maximum
IOP-lowering effect was observed within
60–90 min after the instillation of this compound
and was -3.6 ± 0.9, -5.4 ± 0.7, -6.8 ± 0.7, and
-7.2 ± 1.9 mm Hg, respectively, for the 0.1, 1.0,
10, and 28 mM dosing of H-1152P. As regards the
duration on IOP-lowering action this varied
between 90 min and 7 h depending on the con-
centration employed and was longer with higher
concentrations. No serious side effects were
observed in ocular tissues, except conjunctival
hyperemia observed in some cases, which disap-
peared within 3 h of application.
Following the evidence of IOP-lowering effi-
cacy with the so-far tested ROCK inhibitors, the
synthesis of new molecules is under investiga-
tion. In that respect, Henderson et al. [83] have
recently published a SAR development around
two hits from a kinase library that led to a
number of ROCK inhibitors with sub-500 nM
activity against ROCK 1 and sub-100 nM activ-
ity against ROCK2. One of these compounds,
named 38, had a suitable profile for in vivo
determinations similar to the one found for
H1152. Compound 38 has demonstrated an
average IOP reduction of 33% at the 300-lg dose
and 37% at the 600-lg dose in a hypertensive
model of cymologous monkey. The topical
administration of compound 38 was also asso-
ciated with mild hyperemia, but no discharge or
swelling were evident with this compound.
In order to improve the pharmaceutical
properties of ROCK inhibitors, Yin et al. [84]
have recently designed a series of urea-based
ROCK2 inhibitors with SAR studies performed
on the central phenyl ring and on the urea bond
of the molecules. Importantly, the introduction
of both electron-donating groups and elec-
tron-withdrawing groups to the central phenyl
ring, at the position ortho to the urea group,
generated high ROCK2 potency (1 mM or
below) and high cellular activity. The instilla-
tion of one of these compounds, named 1y, on
Brown Norway rats, reduced IOP around 7 mm
Hg compared with that of the vehicle. The IOP
reduction was observed from 1 to 4 h and
returned to baseline levels approximately 8 h
later. According to this study, the use of urea-
based ROCK inhibitors may offer a promising
option for the future treatment of glaucoma.
However, there is still a need to develop ocular
appropriate toxicology studies to evaluate,
among others, conjunctival hyperemia, a com-
mon adverse event described in long-term
therapies with other ROCK inhibitors. This
hyperemia is believed to derive from a smooth
muscle cell relaxation of conjunctival blood
vessels. It is worth noting that research efforts
under way on the design and synthesis of ROCK
inhibitors aim to convert them into a pre-
dictable, nontoxic metabolite by controlled
metabolic inactivation. In this sense, Van de
Velde and et al. [85] have evaluated the in vivo
safety profile and IOP-lowering potency of
AMA0076, a ROCK1 and ROCK2 inhibitor that
can be inactivated by esterases, thus minimizing
its effect on the ocular surface. Studies to
determine the rate of conversion of AMA0076
into its functionally inactive metabolite were
performed in cornea, conjunctiva, sclera, and
aqueous humour, confirming that the highest
specific activity was found in cornea, followed
by the conjunctiva, sclera, and aqueous humour
(4.81, 1.93, 1.25, 0.14 pmol min-1 mg-1,
respectively). Maximum IOP reduction com-
pared with baseline values after a single dose of
AMA0076 at a concentration of 0.5%, 0.3%, and
0.1% was 48 ± 0.32% (p = 0.03), 39 ± 0.41%
(p = 0.003), and 23 ± 0.17% (p = 0.0006),
respectively. IOP-lowering efficacy lasted 2 h
post-dosing for the 0.5% and 0.3% concentra-
tions, and 4 h post-dosing for the 0.1% con-
centration. In a hypertensive rabbit model,
induced by the injection of a viscous agent in
the anterior chamber of the eye, the topical
application of AMA0076 0.3% and 0.5%, com-
pletely inhibited IOP elevation (p\0.0001)
with minimal conjunctival hyperaemia.
Following the well-documented IOP-lower-
ing efficacy of ROCK inhibitors in multiple
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animal models, a number of clinical trials have
been developed. Further information is pro-
vided in the clinical trials section.
Actin Polymerization Inhibitors
Actin comprises a monomeric unit of microfil-
aments able to spontaneously polymerize into
helical filaments. It is an integral part of the
cytoskeleton and provides mechanical struc-
ture, motility, and contributes to a series of
complex cellular activities in amoeboid and
animal cells [86]. The use of molecules which
can inhibit actin polymerization in conven-
tional pathway cells is currently of great
research interest. Research efforts have concen-
trated on exploring novel mechanisms by
which either the spaces between the inner wall
of SC and the trabecular collagen beams can be
expanded, and/or openings between inner wall
cells can be enlarged. In this sense, studies
employing actin-disrupting agents, such as
cytochalasans and latrunculin, have shown
promising results [26, 50–52, 87].
Cytochalasans are a diverse group of fungal
polyketide-amino acid hybrid metabolites with
diversified distinctive biological functions. The
best known property of cytochalasans is the
capping of actin filaments, preventing their
elongation and affecting several actin-depen-
dent cellular events, such as cell morphogene-
sis, motility, and endocytosis [88]. Latrunculins
are macrolides isolated from the marine sponge
Latrunculia magnifica that sequester monomeric
G-actin, leading to the disassembly of actin fil-
aments and morphological changes in cells [50].
Sanka et al. [89] investigated the activity of
cytochalasin D and latrunculin A on MMP-2
activation in cultured primary human conflu-
ent TM cells. Cells treated with both agents
demonstrated the greatest degree of cell mor-
phology alterations, with rounding-up of cells,
cell–cell separation, and cell detachment, as
well as amendments in staining patterns for
F-actin. A dramatic effect on MMP-2 activation
was also observed by these authors and was
attributed to a reduction of the MMP-2 proform.
It has also been suggested that there is a rela-
tionship between substrate compliance and cell
actin polymerization that might influence the
response of human TM to latrinculin-B [90]. In
non-human primates, the topical administra-
tion of latrinculin-B considerably increased
outflow facility by 123 ± 67% and 272 ± 45%,
respectively with the 0.8- and 4.0-lg doses over
a 90-min period [91]. Further studies in
cynomolgus monkeys and human enucleated
postmortem eyes demonstrated latrunculin B to
significantly enhance the conventional outflow
[25, 26, 50, 52].
As demonstrated by a number of investiga-
tors, the use of actin depolymerizers results in a
meaningful enhancement in outflow activity
and significant improvement in effective filtra-
tion area compared with the controls. These
findings have been corroborated in vivo by
observing a meaningful IOP reduction after the
topical administration of latrinculin-B in
non-human primates. Subsequent to these
experimental results, clinical trials have been
initiated evaluating the safety, tolerability, and
IOP-lowering efficacy of these actin depoly-
merizers in patients with ocular hypertension,
or early POAG. For further information, see the
next section.
PHASE I–III CLINICAL TRIALS
ON NOVEL IOP-LOWERING
COMPOUNDS
This section is focused on novel, ocular
IOP-lowering compounds that are active in
Phases I to III of glaucoma clinical trials within
the past 2 years (until July 2016). More specifi-
cally, we briefly examine IOP-lowering thera-
pies that focus on the mechanism of the
conventional aqueous outflow in relation to
ECM turnover and cell stiffness in the TM and
SC (Table 2). Databases used in these searches
include published articles, meeting abstracts
and Clinical Trial Registry (http://www.
clinicaltrials.gov).
Adenosine Receptor Agonists
Trabodenoson is a highly selective adenosine
mimetic targeting the A1 receptor with the
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potential to lower IOP by increasing conven-
tional outflow facility directly at the TM level.
The administration of this novel molecule has
been shown to significantly increase aqueous
humour outflow facility in Dutch-Belted rab-
bits, ocular normotensive and hypertensive
New Zealand white rabbits, and in isolated
perfused porcine anterior segments [92, 93].
Subsequently, Laties et al. [94] published the
tolerability and safety profile of different doses
of trabodenoson in a randomized, dou-
ble-masked, placebo-controlled dose escalation
study, in which the drug was topically applied
in healthy volunteers (aged 35–76 years) in
doses varying from 200 to 3200 lg [94]. Overall
results were very encouraging with minimal
ocular adverse events encountered that lasted
less than 24 h and were generally mild in
intensity and self-limiting. Although no ante-
rior chamber inflammation or changes in visual
acuity were noted in any of the normal subjects,
the bilateral topical application of trabo-
denoson once daily beginning at 200 lg in 1 eye
and 1600 lg in the fellow eye—with dose esca-
lation every other day thereafter—was associ-
ated with a greater incidence of adverse events
compared with placebo (50 vs. 25%, respec-
tively). Further analysis indicated that there was
no tissue accumulation with repeated dosing,
supporting continued clinical development of
trabodenoson to confirm and better character-
ize its safety and efficacy profile in a sufficient
sample of patients with POAG and ocular
hypertension. Of particular interest in the
future will be the effectiveness of this novel
IOP-lowering compound in secondary glauco-
mas with worse 24-h IOP characteristics than
POAG caused by a functional blockade of the
conventional outflow system (e.g. exfoliative or
pigmentary glaucoma). The direct effect of tra-
bodenoson upon the conventional outflow
facility implies that the efficacy potential of this
adenosine receptor agonist may be greater in
these glaucomas compared with POAG.
In 2016, Myers et al. [95] in a randomized,
double-marked, placebo-controlled, dose esca-
lation study reported the efficacy and safety of 4
trabodenoson doses (50, 100, 200, and 500 lg)
administered twice daily over 14 or 28 days in
subjects with ocular hypertension, or POAG.
There were few treatment-related adverse
events, mainly ocular and conjunctival hyper-
emia detected in 16 subjects treated with tra-
bodenoson (18.8%), of whom 10 subjects
exhibited mild and 6 moderate hyperemia. The
highest dose (500 lg) was associated with the
highest incidence of hyperemia, both before
and after randomization. Consequently, it was
suggested that the hyperemia may have been a
pre-existing pathology rather than an effect of
trabodenoson therapy. With regard to efficacy,
a dose-dependent reduction in IOP was identi-
fied with trabodenoson. For the 500 lg dosing
group at day 28, the IOP reduction ranged
between -3.5 and -5.0 mm Hg (mean reduc-
tion of -4.1 mm Hg), compared to a reduction
between -1.0 and -2.5 mm Hg (mean reduc-
tion of -1.6 mm Hg) for the corresponding
placebo-treated group. Moreover, IOP lowering
seemed to improve with longer exposure to
therapy; IOP reduction at day 29 was signifi-
cantly greater than that seen at day 14
(p = 0.0163). Importantly, in the 500 lg dosing
group, trabodenoson’s IOP-lowering efficacy
lasted at least 24 h after the last dose. Never-
theless, the 24-h efficacy of trabodenoson
remains to be elucidated.
In 2015, Inotek Pharmaceuticals completed a
Phase II study evaluating the adjunctive efficacy
of trabodenoson to latanoprost in subjects with
either ocular hypertension, or POAG (clinical
trial identifier NCT01917383). To date, these
results have not being published. In 2016, the
same company started recruiting participants
for a Phase III study (clinical trial identifier
NCT02565173) that involved the topical appli-
cation, in both eyes, of trabodenoson oph-
thalmic formulation 3.0% or 6.0% once per day,
or trabodenoson 4.5% administered twice daily
in adults with ocular hypertension, or POAG,
with the purpose of assessing the efficacy, tol-
erability, and safety of trabodenoson treatment
for 12 weeks, in comparison with timolol, used
as active control in the study. At the same time,
they have also started recruiting participants for
a Phase II study to evaluate the overall benefit/
risk profile of bilateral, once-daily topical
application of fixed-dose combinations of tra-
bodenoson (3.0% and 6.0%) and latanoprost
(0.05% or 0.0025%) in adults with ocular
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hypertension or POAG (clinical trial identifier
NCT02829996).
In a separate research approach, Acucela Inc.
and Otsuka Pharmaceuticals Co. have per-
formed a Phase I–II study to evaluate the safety,
tolerability, pharmacokinetics, and IOP-lower-
ing efficacy of the adenosine A2 receptor ago-
nist OPA-6566, in a dose-escalation study in
subjects with ocular hypertension, or POAG
(clinical trial identifier NCT01410188). No
study results are currently available.
Nitric Oxide Donors
A phase II study to assess the efficacy and safety
of latanoprost bunod, a NO-donating pros-
taglandin F2a receptor agonist, has recently
been published by Weinreb et al. [96]. The
clinical trial, named the VOYAGER study (clin-
ical trial identifier NCT01223378), was a ran-
domized, investigator-masked, parallel-group,
dose-ranged study designed to compare the
efficacy and safety of 4 different concentrations
of latanoprost bunod ophthalmic solution
against a commercially available formulation of
latanoprost 0.005% ophthalmic solution, in
patients diagnosed with open-angle glaucoma
(including pigmentary or exfoliative glaucoma),
or ocular hypertension. A total of 396 subjects
were randomized and completed this study (76
on latanoprost bunod 0.006%; 81 on latano-
prost bunod 0.012%; 80 on latanoprost bunod
0.024%; 80 on latanoprost bunod 0.040%; and
79 on latanoprost 0.005%). No difference in
treatment effect between equivalent molar
concentrations of either drug was detected. A
dose-dependent increase in efficacy was
observed with latanoprost bunod beyond the
0.006% dose and up to the 0.024% dose,
revealing the dose–response curve for the
NO-donating moiety of latanoprost bunod. In
general, IOP reduction was significantly greater
with latanoprost bunod compared with com-
mercially available latanoprost. The safety
assessment indicated that latanoprost bunod at
concentrations between 0.006% and 0.040%,
dosed once daily for a period of 28 days, was
well tolerated but was associated with a higher
incidence of ocular adverse events. The most
common adverse events encountered were
ocular pain upon instillation and hyperemia,
which were both mild to moderate in severity.
Latanoprost bunod entered a Phase 3 clinical
trial, sponsored by Baush and Lomb that fin-
ished in 2015 (clinical trial identifier
NCT01749904). In July 2016, the FDA did not
identify any efficacy or safety concerns with
respect to the New Drug Application for lata-
noprost bunod 0.024% ophthalmic solution. If
approved, latanoprost bunod 0.024%, formula-
tion licensed by Nicox to Bauch and Lomb,
would be the first once-daily nitric oxide-do-
nating prostaglandin analog in the market
which will lower IOP by increasing aqueous
humour outflow through both the conven-
tional (TM and SC) and the unconventional
(uveoscleral pathway) outflow systems.
Rho Kinase Inhibitors
AR-13324 (netarsudil) is a new class of ocular
hypotensive compounds that inhibits both Rho
Kinase and the norepinephrine transporter.
AR-13324 seems capable of obtaining a signifi-
cant IOP reduction in both rabbits and mon-
keys, with a longer duration of action than
reported for previously characterized ROCK
inhibitors and a mechanism of action that
combines an increase in outflow facility (by
ROCK inhibition) and a concomitant decrease
in aqueous humour production (by nore-
pinephrine transporter inhibition) [97].
In 2012, Aerie Pharmaceuticals sponsored
the first study in patients with elevated IOP that
received ophthalmic solutions of AR-13324
(netarsudil), at 3 different concentrations
(0.01%, 0.02% and 0.04%), dosed once daily for
a period of 7 days (clinical trial identifier
NCT01528787). Netarsudil achieved a signifi-
cant gradual IOP reduction for a period of 8 h
after administration and its effect lasting for
over 24 h. Researchers detected a dose-related
ocular hyperemia that declined in incidence
and severity with repeated dosing [98].
More recently, Bacharach et al. [99] docu-
mented the hypotensive efficacy and safety of
0.01% and 0.02% netarsudil, compared with
latanoprost ophthalmic solution used as
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positive control, in a 28-day study with PM
dosing in subjects with either open-angle glau-
coma, or ocular hypertension. On day 14, mean
diurnal IOP decreased from 25.8 mm Hg,
25.6 mm Hg and 25.5 mm Hg to 19.8 mm Hg,
19.5 mm Hg and 18.4 mm Hg in the 0.01%
netarsudil, 0.02% netarsudil and 0.005% lata-
noprost groups, respectively. On day 28, netar-
sudil did not meet the criteria for
non-inferiority compared to commercially
available latanoprost. Latanoprost and 0.02%
netarsudil were statistically similarly effective at
all timepoints in the subset of patients with
baseline IOPs B26 mm Hg, demonstrating a
reduction in mean diurnal IOP of 7.7 and
5.6 mm Hg, respectively. The most frequently
reported drug-related event was conjunctival/
ocular hyperemia, which was more common
with netarsudil: its incidence was 52% (39/75),
57% (41/72), and 16% (12/77) in the netarsudil
0.01%, netarsudil 0.02%, and latanoprost
groups, respectively (p\0.001). Slit-lamp
examination conducted during safety visits on
day 7 observed mild, or moderate conjunctival
hyperemia in 28% (21/74) and 35% (25/72) of
patients in the netarsudil 0.01% and 0.02%
treatment groups, respectively, in contrast to
only 4% (3/76) of patients in the latanoprost
0.005% group. Overall, conjunctival hyperemia
was seen in more than half of the patients
treated with netarsudil, but it was described by
these investigators as transient due to the lower
incidence scored by slit-lamp examination in
the morning compared to the greater incidence
reported by patients after dosing in the evening.
However, this study did not provide informa-
tion on the long-term efficacy of netarsudil, its
efficacy in patients with a corneal thickness
greater than 600 mm, or in patients with other
forms of glaucoma than open-angle glaucoma.
These should be investigated in the future.
Aerie Pharmaceuticals has also evaluated the
use of PG324 ophthalmic solution, a fixed
combination of netarsudil 0.01%, or 0.02% and
latanoprost 0.005%. A total of 292 patients were
randomized to receive: (1) PG324 0.01%, (2)
PG324 0.02%, (3) netarsudil 0.02%, or (4)
commercially available latanoprost 0.005%
[100]. In this study, both PG324 0.02%
(p\0.0001) and PG324 0.01% (p = 0.0071 and
0.002) fixed combinations met the criterion for
statistical superiority versus the two monother-
apies tested (latanoprost and netarsudil 0.02%).
All four treatments provided statistically
(p\0.0001) and clinically meaningful IOP
decreases (-6.2 to -9.1 mm Hg) in mean diur-
nal IOP from untreated baseline. Moreover,
PG324 0.02% fixed combination obtained mean
IOP between 15.6 and 17 mm Hg across all tes-
ted time points compared to mean IOP between
17.7 and 19.6 mm Hg provided by latanoprost.
Thus, the novel PG324 0.02% fixed combina-
tion was superior to latanoprost monotherapy
by 1.6–3.2 mm Hg. The greater IOP-lowering
effect for PG324 persisted 36 h after last dosing
with a difference of 2.2 mm Hg in favor of
PG324 on day 30. The most frequently reported
adverse event was mild and transient conjunc-
tival hyperemia with an incidence of 41% and
40% for PG324 0.01% and PG324 0.02%,
respectively. In 2016, Aerie Pharmaceuticals
initiated a sponsored phase III study to evaluate
the ocular hypotensive efficacy and safety of the
new fixed combination compared to netarsudil
ophthalmic solution 0.02% and latanoprost
ophthalmic solution 0.005% in patients with
open-angle glaucoma or ocular hypertension
(clinical trial identifier NCT02674854).
It is noteworthy that, in the last 2 years,
another ROCK inhibitor has emerged as a ther-
apeutic molecule with potential to become a
future topical antiglaucoma therapy. This K-115
compound, named ripasudil, has become the
first topical ROCK inhibitor developed for the
treatment of glaucoma or ocular hypertension
in Japan. Initially, ripasudil demonstrated a
meaningful IOP-lowering effect in rabbits and
monkeys [101]. Subsequently, phase I clinical
studies showed its efficacy in healthy adult
volunteers [102]. Furthermore, Tanihara et al.
[103] conducted a multicenter, prospective,
randomized, crossover study for the estimation
of its IOP-lowering efficacy over 24 h in patients
with either ocular hypertension or POAG. These
authors enrolled 43 patients who received
ripasudil 0.2%, ripasudil 0.4%, or placebo in
both eyes twice a day for 3 periods separated by
5–30 days. They established statistically signifi-
cant IOP reductions from baseline for both
dosages of ripasudil and for placebo at all
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time-points except at 24 h after the first instil-
lation (12 h after the second instillation) for the
placebo group. The IOP lowering obtained var-
ied between -2.0 and -4.1 mm Hg in the pla-
cebo group, -5.2 and -6.8 mm Hg in the 0.2%
ripasudil group, and -6.4 and -7.3 mm Hg in
the 0.4% ripasudil group, respectively, at 2 h
after the first and the second instillation [103].
Furthermore, differences in maximum IOP
reductions between placebo and ripasudil-ad-
ministered patients were -3.4 and -2.9 mm Hg
in 0.2% ripasudil group and -4.4 and -3.3 mm
Hg in the 0.4% ripasudil group, respectively,
after the first and the second instillation. Con-
junctival hyperemia was detected in 3 (11%), 22
(79%) and 27 (96%) of the 28 patients, in pla-
cebo, ripasudil 0.2% and ripasudil 0.4%,
respectively. In most cases, however, there was
only mild to moderate conjunctival hyperemia
appearing within 1 h after instillation and only
being evident for 1–3 h.
In a phase III study, Tanihara et al. [104]
conducted a 56-day, multicenter, randomized,
placebo-controlled, double-masked, parallel
group comparison to evaluate additive
IOP-lowering effects and safety of ripasudil
0.4%, in combination with timolol 0.5%, or
latanoprost 0.005%, in patients with ocular
hypertension or POAG [104]. Patients were
randomly assigned to two groups and treated
with ripasudil 0.4% or placebo in addition to
timolol 0.5% or latanoprost 0.005%. The mean
baseline IOP at 0900 hours for the population
analyzed was 19.8 ± 1.8 and 19.8 ± 1.9 mm Hg
in the ripasudil–timolol and ripasudil–la-
tanoprost studies, respectively.
Two hours after instillation (1100 hours)
mean IOP reductions for ripasudil and placebo
were -2.9 and -1.3 mm Hg and -3.2 and
-1.8 mm Hg, respectively, in the ripasudil–ti-
molol and the ripasudil–latanoprost studies.
Statistically significant IOP differences between
ripasudil and placebo were only detected in the
ripasudil–timolol study.
The most frequent adverse event described
with these fixed combinations was conjunctival
hyperemia, with incidence rates of 65.4% and
55.9%, respectively, in the ripasudil–timolol
and ripasudil–latanoprost studies. In almost all
cases, the investigators considered hyperemia to
be drug-related. Even though hyperemia was
observed in most cases after every instillation, it
should be noted that hyperemia was mild in all
cases. Further, in most cases, hyperemia
resolved prior to the next instillation (clinical
trials Japanese identifiers JAPIC111700 and
JAPIC111701).
The use of ripasudil was also evaluated in 92
glaucoma patients who could not be controlled
medically despite the use of maximal tolerated
medical therapy [105]. A total of 43 subjects
with POAG, 28 with normal-tension glaucoma,
10 with secondary glaucoma, 7 with exfoliative
glaucoma, and 4 with developmental glaucoma
received ripasudil as adjunctive therapy. The
mean pre-administration IOP and mean per-
centage of IOP reduction at the last follow-up
were 19.7 ± 4.9 mm Hg and 6.5 ± 17.0% for
POAG, 15.5 ± 2.0 mm Hg and 2.3 ± 10.4% for
normal-tension glaucoma, 22.8 ± 8.3 mm Hg
and 19.1 ± 13.5% for secondary glaucoma,
22.5 ± 4.4 mm Hg and 2.1 ± 14.5% for exfolia-
tive glaucoma, and 20.2 ± 8.9 mm Hg and
11.4 ± 23.1% for developmental glaucoma,
respectively.
Actin Polymerization Inhibitors
As previously discussed, the administration of
latrinculin-B alters the structural geometry of
the TM, by inducing a reduction in cell–cell and
cell–matrix adhesion, along with impairment of
cellular contractility. Consequently, outflow
facility is enhanced by a relaxation of the TM
and SC, which expands the area available for
fluid outflow and reduces resistance to fluid
flow across the system [26, 50–52, 91]. Ras-
mussen et al. [106] evaluated the administration
of latrinculin-B in 14 subjects diagnosed with
ocular hypertension or early POAG in a phase
I-II study, sponsored by Merck Sharp & Dohme
Corp. and developed by Inspire Pharmaceuticals
(clinical trial identifier NCT00443924). Latrin-
culin-B ophthalmic solution (designated as
INS115644) was evaluated in four concentra-
tions: 0.005%, 0.01%, 0.02% and 0.05%. Five
single-dose instillations of INS115644 separated
by approximately 12 h were given over a period
of 3 days to evaluate safety, tolerability, and
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efficacy in a multicenter, double-masked, ran-
domized, placebo-controlled, ascending dose
study. The entry requirements for IOP were
untreated IOP of 22–30 mm Hg at 8 AM (\4 mm
Hg difference between eyes). Following the first
instillation, 0.02% INS115644 reduced IOP by
3.8 ± 2.25 mm Hg (p = 0.002), and 0.05%
INS115644 by 3.9 ± 3.1 mm Hg (p = 0.004)
from baseline at 4 h post instillation. After the
fifth instillation (day 3), IOP decreased from
baseline by 5.4 ± 2.4 mm Hg (p = 0.004), a 24%
reduction in IOP, in the 0.02% cohort and
2.8 ± 2.7 mm Hg (p = 0.02), a 12% reduction, in
the 0.05% cohort at 4 h post instillation.
INS115644 did not significantly lower IOP in
the treated eyes compared with contralateral,
placebo-control eyes at the two lowest doses
tested (0.005% and 0.01%).
Regarding safety evaluation, adverse events
consisted mainly of mild ocular redness and
irritation, although transient changes in central
corneal thickness were noted 4 h post-instilla-
tion. The largest change was an increase of
B2.5% at the 0.05% dose, evaluated by authors
as not statistically significant.
FUTURE DIRECTIONS
As a new strategy for the management of ele-
vated IOP adenosine receptor agonists, nitric
oxide donors, Rho Kinase inhibitors, and actin
polymerization inhibitors have all been repor-
ted to offer a meaningful experimental and
clinical IOP reduction, which may facilitate
glaucoma management. The main drawback of
current antiglaucoma medications is that they
reduce IOP either by decreasing the synthesis of
aqueous humor or by enhancing unconven-
tional outflow facility. In contrast, the agents
discussed in the present review act on the con-
ventional aqueous humour outflow route. They
induce structural or functional changes in the
TM, SC, or both these tissues by a cascade of
complex biological mechanisms that by and
large require further elucidation. It is eminently
logical to target the TM and SC with future
therapies as these are the sites of functional or
anatomical resistance in glaucoma. However, to
successfully develop and commercialize agents
that specifically target these tissues, there is a
need first to better understand the molecular
changes they induce in glaucomatous cells and
the responses to substrate stiffness, as well as
the mechanics of the pore formation or con-
tractility in SC cells. Progress in these important
areas will facilitate adoption of currently tested
drugs and will facilitate the development of new
molecules.
It should be noted that, over the years, sev-
eral candidate drugs targeting SC have failed
during clinical testing, usually due to insuffi-
cient efficacy (e.g. candidate drugs Y39983,
AR-12286, DE-104, ATS907), or due to safety
and tolerability concerns in human subjects
(e.g. candidate drugs INS117548, INS-115644);
[107]. Nevertheless, certain molecules described
here have already provided promising experi-
mental data and initial clinical results demon-
strating potential as future glaucoma therapies
(e.g. trabodenoson, OPA-6566, LTB, netarsudil,
ripasudil, latrunculin-B). Nevertheless, there is a
need for more comprehensive efficacy evidence
(dosing studies, long-term efficacy, 24-h effi-
cacy, efficacy in other glaucomas). Further,
more conclusive evidence is needed with larger
studies that should assess long-term safety and
tolerability. Initial results to date suggest that
these agents, although promising, may still
need improvements in terms of formulation,
delivery mechanisms and administration to
meet desirable safety and efficacy requirements.
However, the overall positive benefit-to-risk
ratio and their novel mechanisms of action
(targeting conventional outflow and especially
SC) should enable some of them to be launched
commercially and to become successful
adjunctive therapies in glaucoma management.
Additional, well-designed, controlled clinical
trials are a vital prerequisite for their further
development and ultimate clinical success.
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